Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Corbus Pharma (NQ: CRBP )

1.740 USD UNCHANGED
Official Closing Price Updated: 7:59 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Corbus Pharma

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Thinking about buying stock in Nantkwest, RealPage, Aerojet Rocketdyne, AIM ImmunoTech, or Corbus Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for NK, RP, AJRD, AIM, and CRBP. 
From PR Newswire
Thinking about buying stock in Titan Pharmaceuticals, Moderna, Moleculin Biotech, Corbus Pharmaceuticals, or Altimmune?
InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT. 
From PR Newswire
Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
From GlobeNewswire News Releases
Corbus Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Updates
From GlobeNewswire News Releases
Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
From GlobeNewswire News Releases
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Corporate Restructuring and Pipeline Portfolio Updates
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
From GlobeNewswire News Releases
Thinking about trading options or stock in Qualcomm, Yandex, Advanced Micro Devices, Estee Lauder, or Corbus Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for QCOM, YNDX, AMD, EL, and CRBP. 
From PR Newswire
Most Popular Robinhood Stocks: $CPRX $CRBP $NRZ
Tags The Market Signal
From The Market Signal
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
From GlobeNewswire News Releases
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
From GlobeNewswire News Releases
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
From GlobeNewswire News Releases
Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
From GlobeNewswire News Releases
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
From GlobeNewswire News Releases
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
From GlobeNewswire News Releases
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
From GlobeNewswire News Releases
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
From GlobeNewswire News Releases
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
From GlobeNewswire News Releases
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
From GlobeNewswire News Releases
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
From GlobeNewswire News Releases
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
From GlobeNewswire News Releases
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
From GlobeNewswire News Releases
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.